RCUS · Arcus Biosciences, Inc.

Arcus Biosciences announced its Q1 2026 financial results alongside significant pipeline developments, highlighting a strategic pivot toward casdatifan as a backbone therapy in clear cell renal cell carcinoma (ccRCC). Financially, revenues declined to $17 million from $28 million year-over-year, driven by lower development services from the Gilead collaboration, reflecting recognition of prior payments as performance obligations are met. R&D expenses remained flat amid increased investments in late-stage casdatifan and quemliclustat's PRISM-1 study, offset by domvanalimab study wind-downs and reduced early-stage costs. G&A rose slightly to $29 million, tied to higher stock-based compensation from an officer separation. Net loss widened to $128 million from $112 million, consistent with ongoing R&D intensity. Balance sheet remains robust with $876 million in cash (down from $1.0 billion at year-end 2025), supporting operations through at least H2 2028 and projecting ~$600 million at 2026-end. Pipeline momentum centers on casdatifan: PEAK-1 Phase 3 enrollment accelerates for IO-experienced ccRCC, targeting completion by year-end alongside 1L Phase 3 initiation with IO combos aiming for TKI-free regimens. ARC-20 data readouts expected in 2026 include mature ORR/PFS for casdatifan+cabozantinib and early-line combos. Quemliclustat's PRISM-1 enrollment completed, results H1 2027. Domvanalimab+zimberelimab NSCLC program discontinued post-futility, streamlining costs. Emerging inflammation assets like AB102 (MRGPRX2 antagonist, clinic Q3 2026), oral TNF inhibitor (early 2027), and CCR6 antagonist (H1 2027) diversify beyond oncology. CEO Terry Rosen emphasized casdatifan's foundational role in ccRCC, with cost efficiencies from streamlining expected to offset casdatifan investments.